ArticleEuropean urology open science2022

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study.

Magnus Lindskog et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.